You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTreprostinil
Accession NumberDB00374  (APRD01272)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTreprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin®. [Wikipedia]
Structure
Thumb
Synonyms
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
Treprostinil
Treprostinilo
Treprostinilum
Uniprost
External Identifiers
  • 15AU81
  • BW 15AU
  • LRX 15
  • U 62840
  • UT 15
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Orenitramtablet, extended release1 mg/1oralUnited Therapeutics Corp.2013-12-20Not applicableUs
Orenitramtablet, extended release2.5 mg/1oralUnited Therapeutics Corp.2013-12-20Not applicableUs
Orenitramtablet, extended release.125 mg/1oralUnited Therapeutics Corp.2013-12-20Not applicableUs
Orenitramtablet, extended release.25 mg/1oralUnited Therapeutics Corp.2013-12-20Not applicableUs
Remodulininjection, solution20 mg/20mLintravenous; subcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
Remodulinsolution5 mgintravenous; subcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
Remodulininjection, solution50 mg/20mLintravenous; subcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
Remodulinsolution10 mgintravenous; subcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
Remodulinsolution1 mgintravenous; subcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
Remodulininjection, solution100 mg/20mLintravenous; subcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
Remodulinsolution2.5 mgintravenous; subcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
Remodulininjection, solution200 mg/20mLintravenous; subcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
Tyvasoinhalant1.74 mg/2.9mLoralUnited Therapeutics Corp.2009-08-14Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Treprostinil diolamine
ThumbNot applicableDBSALT001333
Categories
UNIIRUM6K67ESG
CAS number81846-19-7
WeightAverage: 390.5131
Monoisotopic: 390.240624198
Chemical FormulaC23H34O5
InChI KeyInChIKey=PAJMKGZZBBTTOY-ZFORQUDYSA-N
InChI
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
IUPAC Name
2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid
SMILES
[H][C@]12C[C@@H](O)[[email protected]](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenoxyacetic acid derivatives
Direct ParentPhenoxyacetic acid derivatives
Alternative Parents
Substituents
  • Phenoxyacetate
  • Tetralin
  • Fatty alcohol
  • Alkyl aryl ether
  • Fatty acyl
  • Cyclic alcohol
  • Secondary alcohol
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
PharmacodynamicsPulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.
Mechanism of actionThe major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.
Related Articles
AbsorptionRelatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
Volume of distribution
  • 14 L/70 kg
Protein bindingHuman plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 µ/L.
Metabolism

Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. Whether treprostinil induces these enzymes has not been studied.

Route of eliminationNot Available
Half lifeTerminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.
ClearanceNot Available
ToxicitySymptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier+0.5541
Caco-2 permeable+0.5838
P-glycoprotein substrateSubstrate0.7733
P-glycoprotein inhibitor INon-inhibitor0.719
P-glycoprotein inhibitor IINon-inhibitor0.7518
Renal organic cation transporterNon-inhibitor0.8064
CYP450 2C9 substrateNon-substrate0.7811
CYP450 2D6 substrateNon-substrate0.8144
CYP450 3A4 substrateSubstrate0.6538
CYP450 1A2 substrateInhibitor0.7312
CYP450 2C9 inhibitorNon-inhibitor0.8496
CYP450 2D6 inhibitorNon-inhibitor0.9127
CYP450 2C19 inhibitorNon-inhibitor0.6214
CYP450 3A4 inhibitorNon-inhibitor0.6587
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.8716
CarcinogenicityNon-carcinogens0.9452
BiodegradationNot ready biodegradable0.7495
Rat acute toxicity2.0749 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9588
hERG inhibition (predictor II)Inhibitor0.7664
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • United therapeutics corp
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseoral.125 mg/1
Tablet, extended releaseoral.25 mg/1
Tablet, extended releaseoral1 mg/1
Tablet, extended releaseoral2.5 mg/1
Injection, solutionintravenous; subcutaneous100 mg/20mL
Injection, solutionintravenous; subcutaneous20 mg/20mL
Injection, solutionintravenous; subcutaneous200 mg/20mL
Injection, solutionintravenous; subcutaneous50 mg/20mL
Solutionintravenous; subcutaneous1 mg
Solutionintravenous; subcutaneous10 mg
Solutionintravenous; subcutaneous2.5 mg
Solutionintravenous; subcutaneous5 mg
Inhalantoral1.74 mg/2.9mL
Prices
Unit descriptionCostUnit
Remodulin 10 mg/ml vial737.0USD ml
Remodulin 5 mg/ml vial368.5USD ml
Tyvaso inhalation starter kit185.8USD ml
Remodulin 2.5 mg/ml vial184.25USD ml
Tyvaso 1.74 mg/2.9 ml solution174.55USD ml
Tyvaso inhalation refill kit165.68USD ml
Remodulin 1 mg/ml vial73.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5153222 No1994-10-062014-10-06Us
US6521212 No1998-11-132018-11-13Us
US6756033 No1998-11-132018-11-13Us
US6765117 No1997-10-242017-10-24Us
US7417070 No2006-07-302026-07-30Us
US7544713 No2004-07-142024-07-14Us
US7999007 No2009-03-292029-03-29Us
US8252839 No2004-05-242024-05-24Us
US8349892 No2011-01-222031-01-22Us
US8410169 No2010-02-132030-02-13Us
US8497393 No2008-12-152028-12-15Us
US8653137 No2008-09-052028-09-05Us
US8658694 No2008-09-052028-09-05Us
US8747897 No2009-10-082029-10-08Us
US9050311 No2004-05-242024-05-24Us
US9199908 No2004-05-242024-05-24Us
US9278901 No2004-05-242024-05-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble at 25°CNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00731 mg/mLALOGPS
logP3.53ALOGPS
logP4ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.76ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108 m3·mol-1ChemAxon
Polarizability45.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh, “TREPROSTINIL PRODUCTION.” U.S. Patent US20110319641, issued December 29, 2011.

US20110319641
General ReferencesNot Available
External Links
ATC CodesB01AC21
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (223 KB)
MSDSDownload (17.4 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Treprostinil.
AbciximabTreprostinil may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Treprostinil can be decreased when combined with Abiraterone.
AcebutololTreprostinil may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aceclofenac.
AcenocoumarolTreprostinil may increase the anticoagulant activities of Acenocoumarol.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Treprostinil.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Treprostinil.
AliskirenTreprostinil may increase the hypotensive activities of Aliskiren.
AlprenololTreprostinil may increase the hypotensive activities of Alprenolol.
AlprostadilAlprostadil may increase the anticoagulant activities of Treprostinil.
AlprostadilTreprostinil may increase the antiplatelet activities of Alprostadil.
AlteplaseThe risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.
ALX-0081The risk or severity of adverse effects can be increased when ALX-0081 is combined with Treprostinil.
AmbrisentanTreprostinil may increase the hypotensive activities of Ambrisentan.
AmifostineTreprostinil may increase the hypotensive activities of Amifostine.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aminosalicylic Acid.
AmiodaroneTreprostinil may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Treprostinil can be decreased when combined with Amiodarone.
AmlodipineTreprostinil may increase the hypotensive activities of Amlodipine.
AnagrelideAnagrelide may increase the anticoagulant activities of Treprostinil.
AnagrelideTreprostinil may increase the antiplatelet activities of Anagrelide.
AncrodTreprostinil may increase the anticoagulant activities of Ancrod.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Treprostinil.
AnistreplaseThe risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.
AntipyrineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Antipyrine.
Antithrombin III humanTreprostinil may increase the anticoagulant activities of Antithrombin III human.
ApixabanTreprostinil may increase the anticoagulant activities of Apixaban.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Treprostinil.
ApremilastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Apremilast.
AprepitantThe metabolism of Treprostinil can be increased when combined with Aprepitant.
AprotininThe therapeutic efficacy of Treprostinil can be decreased when used in combination with Aprotinin.
ArdeparinTreprostinil may increase the anticoagulant activities of Ardeparin.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Treprostinil.
ArgatrobanTreprostinil may increase the anticoagulant activities of Argatroban.
Arsenic trioxideTreprostinil may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherTreprostinil may increase the QTc-prolonging activities of Artemether.
AsenapineTreprostinil may increase the QTc-prolonging activities of Asenapine.
AstaxanthinThe risk or severity of adverse effects can be increased when Astaxanthin is combined with Treprostinil.
AtenololAtenolol may increase the hypotensive activities of Treprostinil.
AzapropazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azelastine.
AzelastineAzelastine may increase the anticoagulant activities of Treprostinil.
AzithromycinTreprostinil may increase the QTc-prolonging activities of Azithromycin.
BalsalazideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Balsalazide.
BatroxobinThe risk or severity of adverse effects can be increased when Batroxobin is combined with Treprostinil.
BecaplerminTreprostinil may increase the anticoagulant activities of Becaplermin.
BedaquilineTreprostinil may increase the QTc-prolonging activities of Bedaquiline.
BemiparinThe risk or severity of adverse effects can be increased when Bemiparin is combined with Treprostinil.
BenazeprilTreprostinil may increase the hypotensive activities of Benazepril.
BendroflumethiazideTreprostinil may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Treprostinil.
BenoxaprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Benoxaprofen.
BepridilTreprostinil may increase the hypotensive activities of Bepridil.
BeraprostBeraprost may increase the anticoagulant activities of Treprostinil.
BeraprostTreprostinil may increase the antiplatelet activities of Beraprost.
BetaxololBetaxolol may increase the hypotensive activities of Treprostinil.
BethanidineBethanidine may increase the hypotensive activities of Treprostinil.
BimatoprostTreprostinil may increase the hypotensive activities of Bimatoprost.
BisoprololTreprostinil may increase the hypotensive activities of Bisoprolol.
BivalirudinTreprostinil may increase the anticoagulant activities of Bivalirudin.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Treprostinil.
BosentanTreprostinil may increase the hypotensive activities of Bosentan.
BretyliumTreprostinil may increase the hypotensive activities of Bretylium.
BrimonidineTreprostinil may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Treprostinil.
BromfenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bromfenac.
BupranololTreprostinil may increase the hypotensive activities of Bupranolol.
CandesartanTreprostinil may increase the hypotensive activities of Candesartan.
CandoxatrilTreprostinil may increase the hypotensive activities of Candoxatril.
CangrelorCangrelor may increase the anticoagulant activities of Treprostinil.
CangrelorTreprostinil may increase the antiplatelet activities of Cangrelor.
CapecitabineThe metabolism of Treprostinil can be decreased when combined with Capecitabine.
CaptoprilTreprostinil may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Treprostinil can be decreased when it is combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Treprostinil.
CarprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carprofen.
CarteololTreprostinil may increase the hypotensive activities of Carteolol.
CarvedilolTreprostinil may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Celecoxib.
CeliprololTreprostinil may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Treprostinil can be increased when it is combined with Ceritinib.
CeritinibTreprostinil may increase the QTc-prolonging activities of Ceritinib.
CertoparinTreprostinil may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Chloroquine.
ChlorothiazideTreprostinil may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineTreprostinil may increase the QTc-prolonging activities of Chlorpromazine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Treprostinil.
CholecalciferolThe metabolism of Treprostinil can be decreased when combined with Cholecalciferol.
CilazaprilTreprostinil may increase the hypotensive activities of Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Treprostinil.
CilostazolTreprostinil may increase the antiplatelet activities of Cilostazol.
CiprofloxacinTreprostinil may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideTreprostinil may increase the QTc-prolonging activities of Cisapride.
CitalopramTreprostinil may increase the QTc-prolonging activities of Citalopram.
Citric AcidTreprostinil may increase the anticoagulant activities of Citric Acid.
ClarithromycinTreprostinil may increase the QTc-prolonging activities of Clarithromycin.
ClonidineTreprostinil may increase the hypotensive activities of Clonidine.
ClonixinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin.
ClopidogrelClopidogrel may increase the anticoagulant activities of Treprostinil.
ClopidogrelTreprostinil may increase the antiplatelet activities of Clopidogrel.
ClotrimazoleThe metabolism of Treprostinil can be decreased when combined with Clotrimazole.
ClozapineTreprostinil may increase the QTc-prolonging activities of Clozapine.
CrizotinibTreprostinil may increase the QTc-prolonging activities of Crizotinib.
CryptenamineTreprostinil may increase the hypotensive activities of Cryptenamine.
CyclosporineThe metabolism of Treprostinil can be decreased when combined with Cyclosporine.
CyclothiazideTreprostinil may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe risk or severity of adverse effects can be increased when Treprostinil is combined with D-Limonene.
Dabigatran etexilateTreprostinil may increase the anticoagulant activities of Dabigatran etexilate.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Treprostinil.
DabrafenibThe serum concentration of Treprostinil can be decreased when it is combined with Dabrafenib.
DalteparinTreprostinil may increase the anticoagulant activities of Dalteparin.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Treprostinil.
DanaparoidTreprostinil may increase the anticoagulant activities of Danaparoid.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Treprostinil.
DebrisoquinTreprostinil may increase the hypotensive activities of Debrisoquin.
DefibrotideDefibrotide may increase the anticoagulant activities of Treprostinil.
DefibrotideTreprostinil may increase the antiplatelet activities of Defibrotide.
DelavirdineThe metabolism of Treprostinil can be decreased when combined with Delavirdine.
DeserpidineTreprostinil may increase the hypotensive activities of Deserpidine.
DesirudinTreprostinil may increase the anticoagulant activities of Desirudin.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Treprostinil.
DesmoteplaseThe risk or severity of adverse effects can be increased when Desmoteplase is combined with Treprostinil.
DextranTreprostinil may increase the anticoagulant activities of Dextran.
Dextran 40Treprostinil may increase the anticoagulant activities of Dextran 40.
Dextran 70Treprostinil may increase the anticoagulant activities of Dextran 70.
Dextran 75Treprostinil may increase the anticoagulant activities of Dextran 75.
DiazoxideDiazoxide may increase the hypotensive activities of Treprostinil.
DiclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diclofenac.
DicoumarolTreprostinil may increase the anticoagulant activities of Dicoumarol.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Treprostinil.
DiflunisalThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diflunisal.
DiltiazemDiltiazem may increase the hypotensive activities of Treprostinil.
DipyridamoleDipyridamole may increase the anticoagulant activities of Treprostinil.
DipyridamoleTreprostinil may increase the antiplatelet activities of Dipyridamole.
DisopyramideTreprostinil may increase the QTc-prolonging activities of Disopyramide.
DitazoleThe risk or severity of adverse effects can be increased when Ditazole is combined with Treprostinil.
DofetilideTreprostinil may increase the QTc-prolonging activities of Dofetilide.
DolasetronTreprostinil may increase the QTc-prolonging activities of Dolasetron.
DomperidoneTreprostinil may increase the QTc-prolonging activities of Domperidone.
DorzolamideTreprostinil may increase the hypotensive activities of Dorzolamide.
DoxazosinTreprostinil may increase the hypotensive activities of Doxazosin.
DronedaroneTreprostinil may increase the QTc-prolonging activities of Dronedarone.
DroperidolTreprostinil may increase the QTc-prolonging activities of Droperidol.
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.
DroxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam.
Edetic AcidTreprostinil may increase the anticoagulant activities of Edetic Acid.
EdoxabanTreprostinil may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Treprostinil can be decreased when combined with Efavirenz.
EfonidipineTreprostinil may increase the hypotensive activities of Efonidipine.
EliglustatTreprostinil may increase the QTc-prolonging activities of Eliglustat.
EnalaprilTreprostinil may increase the hypotensive activities of Enalapril.
EnalaprilatTreprostinil may increase the hypotensive activities of Enalaprilat.
EnoxaparinTreprostinil may increase the anticoagulant activities of Enoxaparin.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Treprostinil.
EpinastineEpinastine may increase the anticoagulant activities of Treprostinil.
EpinastineTreprostinil may increase the antiplatelet activities of Epinastine.
EpirizoleThe risk or severity of adverse effects can be increased when Treprostinil is combined with Epirizole.
EpoprostenolTreprostinil may increase the hypotensive activities of Epoprostenol.
EprosartanTreprostinil may increase the hypotensive activities of Eprosartan.
EptifibatideEptifibatide may increase the anticoagulant activities of Treprostinil.
EptifibatideTreprostinil may increase the antiplatelet activities of Eptifibatide.
ErythromycinTreprostinil may increase the QTc-prolonging activities of Erythromycin.
EscitalopramTreprostinil may increase the QTc-prolonging activities of Escitalopram.
EtanerceptThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etanercept.
EthanolEthanol can cause an increase in the absorption of Treprostinil resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ethyl biscoumacetateTreprostinil may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Treprostinil.
EtodolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.
EtravirineThe metabolism of Treprostinil can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Treprostinil is combined with exisulind.
FelodipineTreprostinil may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenbufen.
FenoldopamTreprostinil may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenoprofen.
FibrinolysinThe risk or severity of adverse effects can be increased when Fibrinolysin is combined with Treprostinil.
FlecainideTreprostinil may increase the QTc-prolonging activities of Flecainide.
FloctafenineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Floctafenine.
FloxuridineThe metabolism of Treprostinil can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Treprostinil can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flunixin.
FluorouracilThe metabolism of Treprostinil can be decreased when combined with Fluorouracil.
FluoxetineTreprostinil may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolTreprostinil may increase the QTc-prolonging activities of Flupentixol.
FlurbiprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flurbiprofen.
FluvastatinThe metabolism of Treprostinil can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Treprostinil can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumTreprostinil may increase the anticoagulant activities of Fondaparinux sodium.
FosinoprilTreprostinil may increase the hypotensive activities of Fosinopril.
FosphenytoinThe serum concentration of Treprostinil can be decreased when it is combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Treprostinil.
Gadobenic acidTreprostinil may increase the QTc-prolonging activities of Gadobenic acid.
GemfibrozilThe serum concentration of Treprostinil can be increased when it is combined with Gemfibrozil.
GemifloxacinTreprostinil may increase the QTc-prolonging activities of Gemifloxacin.
GoserelinTreprostinil may increase the QTc-prolonging activities of Goserelin.
GranisetronTreprostinil may increase the QTc-prolonging activities of Granisetron.
GuanabenzTreprostinil may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Treprostinil.
GuanethidineTreprostinil may increase the hypotensive activities of Guanethidine.
GuanfacineTreprostinil may increase the hypotensive activities of Guanfacine.
HaloperidolTreprostinil may increase the QTc-prolonging activities of Haloperidol.
HeparinTreprostinil may increase the anticoagulant activities of Heparin.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Treprostinil.
HexamethoniumTreprostinil may increase the hypotensive activities of Hexamethonium.
HirulogTreprostinil may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Treprostinil is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Treprostinil.
HydralazineTreprostinil may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideTreprostinil may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideTreprostinil may increase the hypotensive activities of Hydroflumethiazide.
IbudilastIbudilast may increase the anticoagulant activities of Treprostinil.
IbudilastTreprostinil may increase the antiplatelet activities of Ibudilast.
IbuprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuproxam.
IbutilideTreprostinil may increase the QTc-prolonging activities of Ibutilide.
IcatibantThe risk or severity of adverse effects can be increased when Treprostinil is combined with Icatibant.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Treprostinil.
Icosapent ethylTreprostinil may increase the antiplatelet activities of Icosapent ethyl.
IfenprodilIfenprodil may increase the anticoagulant activities of Treprostinil.
IfenprodilTreprostinil may increase the antiplatelet activities of Ifenprodil.
IloperidoneTreprostinil may increase the QTc-prolonging activities of Iloperidone.
IloprostIloprost may increase the hypotensive activities of Treprostinil.
IloprostThe risk or severity of adverse effects can be increased when Treprostinil is combined with Iloprost.
IndapamideTreprostinil may increase the hypotensive activities of Indapamide.
IndenololTreprostinil may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Treprostinil can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indoprofen.
IndoraminTreprostinil may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Treprostinil.
IproniazidIproniazid may increase the hypotensive activities of Treprostinil.
IrbesartanTreprostinil may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Treprostinil.
IsoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Treprostinil.
KebuzoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Kebuzone.
KetoconazoleThe metabolism of Treprostinil can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketorolac.
LabetalolTreprostinil may increase the hypotensive activities of Labetalol.
LacidipineTreprostinil may increase the hypotensive activities of Lacidipine.
LatanoprostTreprostinil may increase the hypotensive activities of Latanoprost.
LeflunomideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Leflunomide.
LeflunomideThe metabolism of Treprostinil can be decreased when combined with Leflunomide.
LenvatinibTreprostinil may increase the QTc-prolonging activities of Lenvatinib.
LepirudinTreprostinil may increase the anticoagulant activities of Lepirudin.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Treprostinil.
LercanidipineTreprostinil may increase the hypotensive activities of Lercanidipine.
LeuprolideTreprostinil may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinTreprostinil may increase the QTc-prolonging activities of Levofloxacin.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Treprostinil.
LisinoprilTreprostinil may increase the hypotensive activities of Lisinopril.
LofexidineTreprostinil may increase the hypotensive activities of Lofexidine.
LopinavirThe serum concentration of Treprostinil can be increased when it is combined with Lopinavir.
LopinavirTreprostinil may increase the QTc-prolonging activities of Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.
LosartanTreprostinil may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Treprostinil can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen.
LumacaftorThe serum concentration of Treprostinil can be decreased when it is combined with Lumacaftor.
LumefantrineTreprostinil may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lumiracoxib.
MacitentanTreprostinil may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.
ManidipineTreprostinil may increase the hypotensive activities of Manidipine.
MasoprocolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Treprostinil.
MecamylamineTreprostinil may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole.
MethadoneTreprostinil may increase the QTc-prolonging activities of Methadone.
MethyldopaTreprostinil may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Treprostinil.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Treprostinil.
MetipranololTreprostinil may increase the hypotensive activities of Metipranolol.
MetolazoneTreprostinil may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Treprostinil.
MibefradilTreprostinil may increase the hypotensive activities of Mibefradil.
MifepristoneMifepristone may increase the QTc-prolonging activities of Treprostinil.
MilrinoneMilrinone may increase the anticoagulant activities of Treprostinil.
MilrinoneTreprostinil may increase the antiplatelet activities of Milrinone.
MinaprineMinaprine may increase the hypotensive activities of Treprostinil.
MinoxidilMinoxidil may increase the hypotensive activities of Treprostinil.
MoclobemideMoclobemide may increase the hypotensive activities of Treprostinil.
MoexiprilTreprostinil may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Treprostinil.
MoxifloxacinTreprostinil may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineTreprostinil may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.
NadololTreprostinil may increase the hypotensive activities of Nadolol.
NadroparinTreprostinil may increase the anticoagulant activities of Nadroparin.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Treprostinil.
NaftifineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Treprostinil is combined with NCX 4016.
NCX 4016NCX 4016 may increase the anticoagulant activities of Treprostinil.
NebivololTreprostinil may increase the hypotensive activities of Nebivolol.
NepafenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Treprostinil.
NicardipineTreprostinil may increase the hypotensive activities of Nicardipine.
NicorandilTreprostinil may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Niflumic Acid.
NiguldipineTreprostinil may increase the hypotensive activities of Niguldipine.
NilotinibTreprostinil may increase the QTc-prolonging activities of Nilotinib.
NilvadipineTreprostinil may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nimesulide.
NimesulideNimesulide may increase the anticoagulant activities of Treprostinil.
NimodipineTreprostinil may increase the hypotensive activities of Nimodipine.
NisoldipineTreprostinil may increase the hypotensive activities of Nisoldipine.
NitrendipineTreprostinil may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Treprostinil.
ObinutuzumabTreprostinil may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Treprostinil.
OfloxacinTreprostinil may increase the QTc-prolonging activities of Ofloxacin.
OlmesartanOlmesartan may increase the hypotensive activities of Treprostinil.
OlopatadineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.
OmapatrilatTreprostinil may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe metabolism of Treprostinil can be decreased when combined with Omeprazole.
OndansetronTreprostinil may increase the QTc-prolonging activities of Ondansetron.
OrgoteinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Orgotein.
OtamixabanTreprostinil may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.
OxprenololTreprostinil may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone.
PaliperidoneTreprostinil may increase the QTc-prolonging activities of Paliperidone.
PanobinostatTreprostinil may increase the QTc-prolonging activities of Panobinostat.
ParecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Parecoxib.
PargylineTreprostinil may increase the hypotensive activities of Pargyline.
ParnaparinThe risk or severity of adverse effects can be increased when Parnaparin is combined with Treprostinil.
PazopanibTreprostinil may increase the QTc-prolonging activities of Pazopanib.
PenbutololTreprostinil may increase the hypotensive activities of Penbutolol.
PentamidineTreprostinil may increase the QTc-prolonging activities of Pentamidine.
PentoliniumTreprostinil may increase the hypotensive activities of Pentolinium.
Pentosan PolysulfateTreprostinil may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Treprostinil.
PentoxifyllineTreprostinil may increase the antiplatelet activities of Pentoxifylline.
PerflutrenTreprostinil may increase the QTc-prolonging activities of Perflutren.
PerindoprilTreprostinil may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Treprostinil.
PhenindioneTreprostinil may increase the anticoagulant activities of Phenindione.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Treprostinil.
PheniprazinePheniprazine may increase the hypotensive activities of Treprostinil.
PhenobarbitalThe serum concentration of Treprostinil can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineTreprostinil may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Treprostinil.
PhenprocoumonTreprostinil may increase the anticoagulant activities of Phenprocoumon.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Treprostinil.
PhentolamineTreprostinil may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Phenylbutazone.
PhenytoinThe serum concentration of Treprostinil can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pimecrolimus.
PimozideTreprostinil may increase the QTc-prolonging activities of Pimozide.
PinacidilTreprostinil may increase the hypotensive activities of Pinacidil.
PindololTreprostinil may increase the hypotensive activities of Pindolol.
PirfenidoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Treprostinil.
PiroxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Treprostinil.
PlasminThe risk or severity of adverse effects can be increased when Plasmin is combined with Treprostinil.
PolythiazideTreprostinil may increase the hypotensive activities of Polythiazide.
PrasugrelPrasugrel may increase the anticoagulant activities of Treprostinil.
PrasugrelTreprostinil may increase the antiplatelet activities of Prasugrel.
PrazosinTreprostinil may increase the hypotensive activities of Prazosin.
PrimaquineTreprostinil may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Treprostinil can be decreased when it is combined with Primidone.
ProcainamideTreprostinil may increase the QTc-prolonging activities of Procainamide.
PromazineTreprostinil may increase the QTc-prolonging activities of Promazine.
PropacetamolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Propacetamol.
PropafenoneTreprostinil may increase the QTc-prolonging activities of Propafenone.
PropranololTreprostinil may increase the hypotensive activities of Propranolol.
Protein CTreprostinil may increase the anticoagulant activities of Protein C.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Treprostinil.
ProtocatechualdehydeTreprostinil may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Treprostinil is combined with PTC299.
PyrimethamineThe metabolism of Treprostinil can be decreased when combined with Pyrimethamine.
QuetiapineTreprostinil may increase the QTc-prolonging activities of Quetiapine.
QuinaprilTreprostinil may increase the hypotensive activities of Quinapril.
QuinidineTreprostinil may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the hypotensive activities of Treprostinil.
QuinineTreprostinil may increase the QTc-prolonging activities of Quinine.
RamiprilRamipril may increase the hypotensive activities of Treprostinil.
RasagilineRasagiline may increase the hypotensive activities of Treprostinil.
RemikirenRemikiren may increase the hypotensive activities of Treprostinil.
RescinnamineTreprostinil may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Treprostinil.
ResveratrolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.
ResveratrolResveratrol may increase the anticoagulant activities of Treprostinil.
ReteplaseThe risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.
ReviparinTreprostinil may increase the anticoagulant activities of Reviparin.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Treprostinil.
RidogrelRidogrel may increase the anticoagulant activities of Treprostinil.
RidogrelTreprostinil may increase the antiplatelet activities of Ridogrel.
RifampicinThe serum concentration of Treprostinil can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Treprostinil can be decreased when it is combined with Rifapentine.
RiociguatTreprostinil may increase the hypotensive activities of Riociguat.
RitonavirThe serum concentration of Treprostinil can be increased when it is combined with Ritonavir.
RituximabTreprostinil may increase the hypotensive activities of Rituximab.
RivaroxabanTreprostinil may increase the anticoagulant activities of Rivaroxaban.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Treprostinil.
RofecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Rofecoxib.
RosiglitazoneThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Treprostinil.
SafrazineSafrazine may increase the hypotensive activities of Treprostinil.
SalicylamideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salsalate.
SaprisartanTreprostinil may increase the hypotensive activities of Saprisartan.
SaquinavirTreprostinil may increase the QTc-prolonging activities of Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Treprostinil.
SCH-530348Treprostinil may increase the antiplatelet activities of SCH-530348.
SecobarbitalThe serum concentration of Treprostinil can be decreased when it is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Treprostinil.
SelexipagTreprostinil may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Seratrodast.
SevofluraneSevoflurane may increase the anticoagulant activities of Treprostinil.
SevofluraneTreprostinil may increase the antiplatelet activities of Sevoflurane.
SildenafilSildenafil may increase the antihypertensive activities of Treprostinil.
SitaxentanTreprostinil may increase the hypotensive activities of Sitaxentan.
SorafenibThe metabolism of Treprostinil can be decreased when combined with Sorafenib.
SotalolTreprostinil may increase the QTc-prolonging activities of Sotalol.
SpiraprilTreprostinil may increase the hypotensive activities of Spirapril.
SRT501The risk or severity of adverse effects can be increased when Treprostinil is combined with SRT501.
SRT501SRT501 may increase the anticoagulant activities of Treprostinil.
StiripentolThe serum concentration of Treprostinil can be increased when it is combined with Stiripentol.
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.
SulfadiazineThe metabolism of Treprostinil can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Treprostinil can be decreased when combined with Sulfamethoxazole.
SulfasalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulfasalazine.
SulfisoxazoleTreprostinil may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Treprostinil can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulindac.
SulodexideTreprostinil may increase the anticoagulant activities of Sulodexide.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Treprostinil.
SuprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Treprostinil.
TelavancinTreprostinil may increase the QTc-prolonging activities of Telavancin.
TelithromycinTreprostinil may increase the QTc-prolonging activities of Telithromycin.
TelmisartanTreprostinil may increase the hypotensive activities of Telmisartan.
TemocaprilTreprostinil may increase the hypotensive activities of Temocapril.
TenecteplaseThe risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.
TenoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Teriflunomide.
TerlipressinTreprostinil may increase the hypotensive activities of Terlipressin.
TesmilifeneTesmilifene may increase the anticoagulant activities of Treprostinil.
TesmilifeneTreprostinil may increase the antiplatelet activities of Tesmilifene.
TetrabenazineTreprostinil may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineTreprostinil may increase the QTc-prolonging activities of Thioridazine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tiaprofenic acid.
TiboloneTreprostinil may increase the hypotensive activities of Tibolone.
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Treprostinil.
TiclopidineTiclopidine may increase the anticoagulant activities of Treprostinil.
TiclopidineTreprostinil may increase the antiplatelet activities of Ticlopidine.
TicrynafenTreprostinil may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Treprostinil.
TinzaparinThe risk or severity of adverse effects can be increased when Tinzaparin is combined with Treprostinil.
TirofibanTirofiban may increase the anticoagulant activities of Treprostinil.
TirofibanTreprostinil may increase the antiplatelet activities of Tirofiban.
TolazolineTreprostinil may increase the hypotensive activities of Tolazoline.
TolbutamideThe metabolism of Treprostinil can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Treprostinil.
TorasemideTorasemide may increase the hypotensive activities of Treprostinil.
ToremifeneTreprostinil may increase the QTc-prolonging activities of Toremifene.
TrandolaprilTreprostinil may increase the hypotensive activities of Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tranilast.
TranilastTranilast may increase the anticoagulant activities of Treprostinil.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Treprostinil.
TranylcypromineTranylcypromine may increase the hypotensive activities of Treprostinil.
TrapidilTrapidil may increase the anticoagulant activities of Treprostinil.
TrapidilTreprostinil may increase the antiplatelet activities of Trapidil.
TravoprostTravoprost may increase the hypotensive activities of Treprostinil.
TrichlormethiazideTreprostinil may increase the hypotensive activities of Trichlormethiazide.
TriflusalTriflusal may increase the anticoagulant activities of Treprostinil.
TriflusalTreprostinil may increase the antiplatelet activities of Triflusal.
TrimazosinTreprostinil may increase the hypotensive activities of Trimazosin.
TrimethaphanTreprostinil may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Treprostinil can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Treprostinil.
UnoprostoneTreprostinil may increase the hypotensive activities of Unoprostone.
UrokinaseThe risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.
ValdecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Valdecoxib.
Valproic AcidThe metabolism of Treprostinil can be decreased when combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Treprostinil.
VandetanibTreprostinil may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the antihypertensive activities of Treprostinil.
VemurafenibTreprostinil may increase the QTc-prolonging activities of Vemurafenib.
VorapaxarVorapaxar may increase the anticoagulant activities of Treprostinil.
VorapaxarTreprostinil may increase the antiplatelet activities of Vorapaxar.
VoriconazoleThe metabolism of Treprostinil can be decreased when combined with Voriconazole.
WarfarinTreprostinil may increase the anticoagulant activities of Warfarin.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Treprostinil.
XimelagatranTreprostinil may increase the anticoagulant activities of Ximelagatran.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Treprostinil.
XylometazolineTreprostinil may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Treprostinil.
ZafirlukastThe metabolism of Treprostinil can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zileuton.
ZiprasidoneTreprostinil may increase the QTc-prolonging activities of Ziprasidone.
ZomepiracThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zomepirac.
ZuclopenthixolTreprostinil may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH: Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1161-70. doi: 10.1164/rccm.201001-0011OC. Epub 2010 Jul 9. [PubMed:20622039 ]
  2. Sprague RS, Bowles EA, Hanson MS, DuFaux EA, Sridharan M, Adderley S, Ellsworth ML, Stephenson AH: Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation. 2008 Jul;15(5):461-71. doi: 10.1080/10739680701833804. [PubMed:18574748 ]
  3. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53. [PubMed:15163595 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as ...
Gene Name:
PPARD
Uniprot ID:
Q03181
Molecular Weight:
49902.99 Da
References
  1. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA: Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol. 2006 Feb;34(2):242-6. Epub 2005 Oct 20. [PubMed:16239641 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K: Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34. doi: 10.1177/0091270009351173. Epub 2010 Feb 4. [PubMed:20133511 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:22